KOD
Kodiak Sciences Inc
$41.01
-6.11%
2026-05-08
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Key Fundamentals
Forward P/E
-12.49
EPS (TTM)
$-4.32
ROE
-149.5%
Profit Margin
0.0%
Debt/Equity
37.60
Price/Book
16.71
Beta
2.32
Market Cap
$2.65B
Avg Volume (10D)
536K
Recent Breakout Signals
No recent breakout signals detected for KOD.
Recent Price Range (60 Days)
60D High
$47.84
60D Low
$21.00
Avg Volume
1.1M
Latest Close
$41.01
Get breakout alerts for KOD
Sign up for Breakout Scanner to receive daily notifications when KOD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Kodiak Sciences Inc (KOD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KOD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KOD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.